Milan, Italy, October 6, 2026
Kedrion is participating in CPHI Milan 2026, taking place from October 6 to 8 at Fiera Milano, bringing its expertise in plasma-derived therapies to one of the pharmaceutical industry’s major international gatherings. The company’s presence highlights its capabilities across plasma collection, research, development, manufacturing and distribution, while providing an opportunity to engage with healthcare companies, industry experts, customers and potential partners from around the world.
Kedrion Showcases Plasma-Derived Therapy Expertise
At CPHI Milan 2026, Kedrion is presenting its integrated capabilities supporting the development and production of plasma-derived medicines. The company is engaging with an international audience to discuss its experience in addressing the needs of people living with rare and serious diseases. Kedrion’s participation brings together professionals from Business Development, Commercial, Marketing, Finance, and Research & Innovation, demonstrating the broad organizational expertise involved in advancing plasma-derived therapies. The event also creates opportunities for the company to strengthen relationships with customers, collaborators and pharmaceutical industry peers while discussing evolving requirements across the global healthcare landscape. Plasma-derived therapies remain an important component of treatment for several serious and rare conditions, making reliable plasma supply, advanced manufacturing and international distribution critical elements of the pharmaceutical ecosystem.
Manufacturing Investment Supports Global Supply
A key aspect of Kedrion’s broader strategy is its continued investment in manufacturing capacity and pharmaceutical production infrastructure. The company is highlighting its ongoing expansion of its manufacturing site in Bolognana, Italy, as part of efforts to increase production capacity and support the availability of plasma-derived medicines. As worldwide demand for these therapies continues to develop, investment in manufacturing capabilities can play an important role in strengthening supply and supporting patient access. Kedrion’s activities span multiple stages of the value chain, from plasma collection and scientific research to development, manufacturing and distribution, providing an integrated platform for supplying plasma-derived products to international markets. Its participation at CPHI Milan offers an opportunity to discuss how scientific expertise, industrial capabilities and collaboration can contribute to meeting changing healthcare needs.
Advertisement
CPHI Milan Strengthens Global Healthcare Collaboration
CPHI Milan provides Kedrion with a platform to connect with the wider global pharmaceutical and healthcare community. The event brings together companies, decision-makers and experts to exchange knowledge, explore business opportunities and develop partnerships across the pharmaceutical supply chain. Kedrion’s participation underscores the importance of collaboration in advancing the availability of essential plasma-derived medicines and strengthening connections between scientific, commercial and manufacturing organizations. Visitors can meet the Kedrion team at booth 16H48 during the event and learn more about the company’s activities and capabilities. Through its presence at CPHI Milan 2026, Kedrion is contributing to discussions surrounding plasma therapies, pharmaceutical manufacturing, scientific innovation and global patient access. The company’s continued focus on expanding capabilities and engaging with international stakeholders reflects the importance of coordinated efforts to support the future supply of plasma-derived therapies worldwide.
Source: Kedrion press release
